Biocon Limited · NSE:BIOCON
Biocon — Q1 FY27 Earnings Presentation
16 slides from Biocon's earnings presentation, Aug 6, 2026
Slide 1: Exchange filing cover letter
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/51 August 06, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Cor
Slide 2: Biocon Limited Q1 FY27 Earnings Call
Biocon Limited Q1 FY27 Earnings Call 06 – Aug – 2026
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Chairperson's Opening Remarks
Chairperson’s Opening Remarks
Slide 5: Positioned for the Next Phase of Growth
Positioned for the Next Phase of Growth ▪ Integrated platform, global scale and resilient supply networks position Biocon for sustained growth ▪ North America: largest strategic market, policy tailwinds and launch execution ⁻ Affordability and access remain central to policy dialogue ⁻ Recent US com
Slide 6: Financial Highlights – Q1 FY27
Financial Highlights – Q1 FY27
Slide 7: Financial Highlights – Q1 FY27
Financial Highlights – Q1 FY27 In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% Biopharmaceuticals - Biosimilars 2,855 2,458 2,756 16 4 - Generics 760 630* 776* 21 (2) Services 736 875 1,037 (16) (29) Revenue from Operations 4,336 3,942 4,517 10 (4) Total Revenue 4,391 4,022 4,569 9 (-4) R&D (Net) 240 205
Slide 8: Biosimilars
Biosimilars
Slide 9: Biosimilars: Q1 FY27 Business Performance Update
Biosimilars: Q1 FY27 Business Performance Update ▪ Financial Performance In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% ⁻ Growth led primarily by North America market ⁻ EBITDA up 10% YoY, 25% EBITDA margin Segment 2,855 2,458 2,756 16 4 Revenue ⁻ R&D spend at 7% of revenue R&D 192 134 188 44 2 ▪ Growth m
Slide 10: Generics
Generics
Slide 11: Generics: Q1 FY27 Business Performance Update
Generics: Q1 FY27 Business Performance Update ▪ Financial Performance In ₹ Cr Q1 FY27 Q1 FY26* Q4 FY26* YoY% QoQ% ⁻ Revenues up 21% YoY ⁻ EBITDA margin up by over 250bps QoQ Segment 760 630 776 21 (2) Revenue ⁻ R&D spend at 6% of revenue R&D 47 70 89 (33) (47) ▪ Generic liraglutide was a key driver
Slide 12: Services
Services
Slide 13: Services: Q1 FY27 Business Performance Update
Services: Q1 FY27 Business Performance Update ▪ Financial Performance ⁻ Performance impacted by lower offtake from a key biologics In ₹ Cr Q1 FY27 Q1 FY26 Q4 FY26 YoY% QoQ% client and forex hedge losses ⁻ Partly offset by cost optimization initiatives Segment 736 875 1,037 (16) (29) Revenue ▪ Streng
Slide 14: Concluding Remarks
Concluding Remarks
Slide 15: Concluding Remarks: Q1 FY27
Concluding Remarks: Q1 FY27 ▪ Growth Momentum Building ⁻ Recent launches and expanded manufacturing capacity support the next phase of growth ⁻ Performance expected to strengthen through FY27, led by Biosimilars ▪ Translating Scale into Returns ⁻ Focused on improving margins, free cash flow generati
Slide 16: Thank you Q&A
SCIENCE FOR PEOPLE ; ADVANCING IMPACT $Biocon Q&A